The market impacts of pharmaceutical product patents in developing countries: Evidence from India

American Economic Review

Volumn 106, Issue 1, 2016, Pages 99-135

  Duggan, Mark ^a   Garthwaite, Craig ^b   Goyal, Aparajita ^c  

^a STANFORD UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c WORLD BANK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84979239897     PISSN: 00028282     EISSN: None     Source Type: Journal    
DOI: 10.1257/aer.20141301     Document Type: Article

References (49)

1. Abbot, Frederick, Amy Kapczynski, and T. N. Srinivasan. 2005. "The Draft Patent Law." The Hindu, March 12, 2005. http://www.thehindu.com/2005/03/12/stories/2005031201151000.htm (accessed August 30, 2014).
2. Acemoglu, Daron, and Joshua Linn. 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry." Quarterly Journal of Economics 119 (3): 1049-90.
3. Ahmed, Rumman. 2012. "India Revokes Roche Patent." Wall Street Journal, November 3.
4. Ahmed, Rumman, and Amol Sharma. 2012. "Novartis Fights India for Cancer Pill Patent." Wall Street Journal, August 19.
5. Alazarki, Melly. 2011. "The 10 Biggest-Selling Drugs That Are About to Lose Their Patent." Daily Finance, February 27.
6. Bajaj, Vikas, and Andrew Pollack. 2012. "India Order Bayer to License a Patented Drug," New York Times, March 12.
7. Berndt, Ernst, and Iain Cockburn. 2014. "The hidden cost of low prices: limited access to new drugs in India." Health Affairs 33 (9): 1567-75.
8. Bertrand, Marianne, Simeon Djankov, Rema Hanna, and Sendhil Mullainathan. 2007. "Obtaining a Driver's License in India: An Experimental Approach to Studying Corruption." Quarterly Journal of Economics 122 (4): 1639-76.
9. Chatterjee, Patralekha. 2005. "India's new patent laws may still hurt generic drug supplies." Lancet 365 (9468): 1378.
10. Chaudhuri, Shubham, Pinelopi K. Goldberg, and Panle Jia. 2006. "Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India." American Economic Review 96 (5): 1477-1514.
11. Chaudhuri, Sudip, Chan Park, and K. M. Gopakumar. 2010. "Five Years Into the Product Patent Regime: India's Response." http://apps.who.int/medicinedocs/documents/s17761en/s17761en.pdf (accessed November 1, 2015).
12. Chowdhury, Anirban. 2013. "India Widens Price Control Over Medicines." Wall Street Journal, May 17.
13. Doshi, Tishani. 2004. "AIDS: Drug Wars." The Hindu, July 11. http://www.thehindu.com/thehindu/mag/2004/07/11/stories/2004071100160200.htm (accessed November 1, 2015).
14. Dranove, David, Craig Garthwaite, and Manuel Hermosilla. 2014. "Pharmaceutical Profits and the Social Value of Innovation." National Bureau of Economic Research Working Paper 20212.
15. Duggan, Mark, Craig Garthwaite, and Aparajita Goyal. 2016. "The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India: Dataset." American Economic Review. http://dx.doi.org/10.1257/aer.20141301.
16. Duggan, Mark G., and Fiona Scott Morton. 2011. "The Medium-Term Impact of Medicare Part D on Pharmaceutical Prices." American Economic Review 101 (3): 387-92.
17. Dugger, Cecilia. 2001. "A Catch-22 on Drugs for the World's Poor." New York Times, Nov 16. http://www.nytimes.com/2001/11/16/business/a-catch-22-on-drugs-for-the-world-s-poor.html.
18. Ellison, Glenn, and Sara Fisher Ellison. 2011. "Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration." American Economic Journal: Microeconomics 3 (1): 1-36.
19. Ellison, Sara Fisher, and Catherine Wolfram. 2006. "Coordinating on Lower Prices: Pharmaceutical Pricing under Political Pressure." RAND Journal of Economics 37 (2): 324-40.
20. Erfle, Stephen, and Henry McMillan. 1990. "Media, Political Pressure, and the Firm: The Case of Petroleum Pricing in the Late 1970s." Quarterly Journal of Economics 105 (1): 115-34.
21. Finkelstein, Amy. 2004. "Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry." Quarterly Journal of Economics 119 (2): 527-64.
22. Fisman, Raymond, and Shang-Jin Wei. 2004. "Tax Rates and Tax Evasion: Evidence from 'Missing Imports' in China." Journal of Political Economy 112 (2): 471-96.
23. Glazer, Amihai, and Henry McMillan. 1992. "Pricing by the Firm under Regulatory Threat." Quarterly Journal of Economics 107 (3): 1089-99.
24. Goldberg, Pinelopi Koujianou. 2010. "Alfred Marshall Lecture: Intellectual Property Rights Protection in Developing Countries: The Case of Pharmaceuticals." Journal of the European Economic Association 8 (2-3): 326-53.
25. Goolsbee, Austan, and Chad Syverson. 2008. "How Do Incumbents Respond to the Threat of Entry? Evidence from the Major Airlines." Quarterly Journal of Economics 123 (4): 1611-33.
26. Government of India. 2010. "List of Controlled Bulk Drugs." National Pharmaceutical Pricing Authority. http://www.nppaindia.nic.in/bulkdruglist.html (accessed November 1, 2015).
27. Greene, William. 2007. "The Emergence of India's Pharmaceutical Industry and Implications for the U.S. Generic Drug Market." United States International Trade Commission No. 2007-05-A.
28. Harris, Gardiner, and Katie Thomas. 2013. "Low Cost Drugs in Poor Nations Get a Lift in Indian Court." New York Times, April 1. http://www.nytimes.com/2013/04/02/business/global/top-courtin-india-rejects-novartis-drug-patent.html?-r=0 (accessed November 1, 2015).
29. Hason, Averie, and Jean Shimotake. 2006. "Recent Developments in Patent Rights for Pharmaceuticals in China and India." Pace International Law Review 18 (1): 303-315.
30. Hemphill, C. Scott, and Bhaven N. Sampat. 2011. "When Do Generics Challenge Drug Patents?" Journal of Empirical Legal Studies.
31. IMS. 2006. "IMS MIDAS Quantum Data Elements, Measures and Statistics 2006."
32. IMS Health. 2012. The Global Use of Medicines: Outlook Through 2016. Parsippany, NJ: IMS Institute for Healthcare Informatics. http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%20 2011/Medicines-Outlook-Through-2016-Report.pdf (accessed November 1, 2015).
33. Kallummal, Murali, and Kavita Bugalya. 2012. "Trends in India's Trade in Pharmaceutical Sector: Some Insights." Center for WTO Studies Working Paper 200/2.
34. Kurzius, Alexa. 2013. "The power of patents: Advocacy groups fear a win for Novartis in India's patent law case will affect affordable access to medicine worldwide." Science Line. http://scienceline.org/2013/01/the-power-of-patents/ (accessed November 1, 2015).
35. Kyle, Margaret K., and Anita M. McGahan. 2012. "Investments in Pharmaceuticals before and after TRIPS." Review of Economics and Statistics 94 (4): 1157-72.
36. Kyle, Margaret, and Yi Qian. 2014. "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS." National Bureau of Economic Research Working Paper 20799.
37. La Croix, S., and M. Liu. 2008. "Patents and Access to Essential Medicines" In Frontiers of Economics and Globalization, 423-64. Amsterdam: Elsevier.
38. Langer, Eric, and Abhijeet Kelkar. 2008. "Pharmaceutical Distribution in India." http://www.biopharminternational.com/pharmaceutical-distribution-india (accessed November 1, 2015).
39. Lanjouw, Jean O., and Iain Cockburn. 2001. "Do Patents Matter? Empirical Evidence After GATT." National Bureau of Economic Research Working Paper 7495.
40. McLain, Sean. 2014. "India Imposes Price Controls on Diabetes and Heart-Disease Drugs." Wall Street Journal, July 14. http://www.wsj.com/articles/india-imposes-price-controls-on-diabetes-and-heartdisease-drugs-1405346553 (accessed November 1, 2015).
41. Milgrom, Paul, and John Roberts. 1982. "Limit Pricing and Entry under Incomplete Information: An Equilibrium Analysis." Econometrica 50 (2): 443-59.
42. Moser, Petra. 2005. "How Do Patent Laws Influence Innovation? Evidence from Nineteenth-Century World's Fairs." American Economic Review 95 (4): 1214-36.
43. Mueller, Janice. 2007. "The Tiger Awakens: The Tumultuous Transformation of India's Patent System and the Rise of Indian Pharmaceutical Innovation." University of Pittsburgh Law Review 68: 491-641.
44. Nordhaus, William D. 1969. Invention, Growth and Welfare: A Theoretical Treatment of Technological Change. Cambridge, MA: MIT Press.
45. Saha, Debabrata. 2004. "Proposal for Establishing a Development Agenda for WIPO." http://www.cptech.org/ip/wipo/india10012004.html (accessed August 30, 2014).
46. Sampat, Bhaven. 2010. "Institutional Innovation or Institutional Imitation? The Impacts of TRIPs on India's Patent Law and Practice." http://www.wipo.int/edocs/mdocs/mdocs/en/wipo-ip-econ-ge-6-10/wipo-ip-econ-ge-6-10-ref-sampat.pdf (accessed November 1, 2015).
47. Sampat, Bhaven, Ken Shadlen, and Tahir Amin. 2012. "Challenges to India's Pharmaceutical Patent Laws." Science 337 (6093): 414-15.
48. Silverman, Ed. 2014. "How Much? Gilead Will Charge $900 for Hepatitis C Treatment in India." Wall Street Journal, August 8. http://blogs.wsj.com/pharmalot/2014/08/07/how-much-gilead-willcharge- 900-for-sovaldi-in-india/ (accessed November 1, 2015).
49. Taylor, Lynne. 2008. "Indian drug prices to drop following budget cuts." Pharma Times, March 4. http://www.pharmatimes.com/article/08-03-04/Indian-drug-prices-to-drop-following-budget-cuts.aspx (accessed November 1, 2015).